What should I avoid while taking Ticlopidine 250mg tablets?

Take with a high fat meal. High fat meals will increase ticlopidine absorption. Take with food. Food can help ticlopidine-induced stomach upset. (Source: DrugBank, licensed under CC BY-NC 4.0)

Do I need a prescription for Ticlopidine 250mg tablets?

Ticlopidine 250mg tablets is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Ticlopidine 250mg tablets?

Ticlopidine 250mg tablets is the generic name. It is available under brand names including: Ticlid 250mg tablets, Ticlopidine 250mg tablets. (Source: NHS dm+d — Actual Medicinal Products)

Ticlopidine 250mg tablets

Prescription only

Requires a prescription from a doctor or prescriber

Tablet

250mg

Oral

Ticlopidine is an effective inhibitor of platelet aggregation.

Active ingredients:

Ticlopidine

BNF classificationBrowse formulary

Where this medicine sits in the British National Formulary — the UK's standard prescribing reference

BNF 02.09

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC B01AC05

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Check interactions for Ticlopidine

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Ticlopidine

Source: MHRA Products DatabaseOGL 3.0

Updated 3 months ago(16 Jan 2026)

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Ticlopidine

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Ticlopidine

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

2 branded products available

2 productsShow details

2 products

Possibly available on the UK marketRestricted supplyDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Ticlopidine on the MHRA register

Ticlopidine 250mg tablets

Special Order

None

Special

Ticlid 250mg tablets

Sanofi-Synthelabo Ltd

Discontinued

Source: NHS dm+dOGL 3.0

Updated about 1 month ago(1 Mar 2026)

Daily doseShow details

WHO defined daily dose (DDD)

500 mg

Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.

Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.

Therapeutically similar medicines

10 similarShow details

Treprostinil 10mg/10ml solution for infusion vials

Infusion

10mg/10ml

Same therapeutic group

Treprostinil 100mg/10ml solution for infusion vials

Infusion

100mg/10ml

Same therapeutic group

Treprostinil 25mg/10ml solution for infusion vials

Infusion

25mg/10ml

Same therapeutic group

Treprostinil 50mg/10ml solution for infusion vials

Infusion

50mg/10ml

Same therapeutic group

Treprostinil 200mg/20ml solution for infusion vials

Infusion

200mg/20ml

Same therapeutic group

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Show details

Loading prescribing data...

Clinical guidelines and formulary information

British National Formulary

Ticlopidine

BNF

Drug monograph — bnf.nice.org.uk

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

NICE clinical guidance(2)

Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (TA335)

TA335

Technology appraisal

Updated Mar 2015

Head injury: assessment and early management (NG232)

NG232

NICE guideline

Updated May 2023

Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Ticlopidine

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

42216711000001105

dm+d ID

42216711000001105

VTM (Virtual Therapeutic Moiety)

777768001

VMP (Virtual Medicinal Product)

42216711000001105

BNF code

02090000

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

B01AC05

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

35 found

Half-life

7.9 hours

Mechanism

The active metabolite of ticlopidine prevents binding of adenosine diphosphate (…

Food interactions

2 warnings

Human targets

2 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

80%

Absorption is greater than 80%. Food increases absorption by approximately 20%.

Half-life

250-mg

Half-life following a single 250-mg dose is approximately 7.9 hours in subjects 20 to 43 years of age and 12.6…

Protein binding

98%

Binds reversibly (98%) to plasma proteins, mainly to serum albumin and lipoproteins.…

Volume of distribution

The volume of distribution was not quantified.

Metabolism

Ticlopidine is metabolized extensively by the liver with only trace amounts of intact drug detected. At least 20 metabolites have been identified.

Elimination

60%

Ticlopidine is eliminated mostly in the urine (60%) and somewhat in the feces (23%).

Clearance

Ticlopidine clearance was not quantified, but clearance decreases with age.

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Small molecule

About this compound

Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who cannot take aspirin or in whom aspirin has not worked to prevent a thrombotic stroke. The FDA label includes a black-box warning of neutropenia, aplastic anemia, thrombotic thrombocytopenia purpura, and agranulocytosis, so it is necessary to monitor patients' WBC and platelets when they are taking ticlopidine.

Properties:

solid

Avg. mass: 263.79 Da

View FDA drug label

DrugBank indication

Used in patients, who have had a stroke or stroke precursors and who cannot take aspirin or aspirin has not worked, to try to prevent another thrombotic stroke.

Also known as(68)

Ticlopidina

Ticlopidine

Ticlopidinum

ADP-glucose receptor

ADPG-R

HORK3

P2T(AC)

P2Y(AC)

Dosage forms(13)

Tablet (Oral)

Tablet, sugar coated (Oral) — 250 mg

Tablet, film coated (Oral)

Tablet, film coated (Oral) — 250 mg/1

Tablet (Oral) — 250 mg

Tablet (Oral) — 250 mg / tab

Pill (Oral) — 250 MG

Tablet, coated (Oral)

Molecular properties(18)

Drug interactions(1470)

Known interactions with other medications. Always consult a healthcare professional.

Apixaban

Unknown severity

DB06605

The risk or severity of adverse effects can be increased when Ticlopidine is combined with Apixaban.

Ticlopidine 250mg tablets

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

NHS reimbursement price

WHO defined daily dose (DDD)

Medicines like this

Prescribing statistics

Guidance (NICE / BNF)

British National Formulary

NICE clinical guidance(2)

Availability, stocks & shortages

Pharmacy stock checkers

Supply & product information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science12

Chemical identifiers

Ticlopidine

Additional database identifiers

International reference pricing

DrugBank citations

Deep science
12